ACADIA Pharmaceuticals Inc.
ACAD
Helyezés a részvények között
#4407
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Részvényárfolyam
$20.40
Piaci kapitalizáció
$3.52B
Változás (1 nap)
1.04%
Változás (1 év)
-4.63%
Ország
US
Kereskedés ACADIA Pharmaceuticals Inc. (ACAD)
Kategória
Healthcare
ACADIA Pharmaceuticals Inc. (ACAD) részvényárfolyamának története
Legmagasabb napi záróár: $19.73 ekkor: 2026-10-01
Legalacsonyabb napi záróár: $6.66 ekkor: 2004-05-01
Legalacsonyabb napi záróár: $6.66 ekkor: 2004-05-01
ACADIA Pharmaceuticals Inc. részvényárfolyamának története 2004 és 2026 között
Éves részvényárfolyam teljesítmény
| Év | Teljesítmény |
|---|---|
| 2026 (TTM) | -10.51% |
| 2025 | 55.58% |
| 2024 | -35.30% |
| 2023 | 74.02% |
| 2022 | -32.82% |
| 2021 | -57.69% |
| 2020 | 18.76% |
| 2019 | 165.62% |
| 2018 | -42.16% |
| 2017 | 8.65% |
| 2016 | -22.24% |
| 2015 | 11.41% |
| 2014 | 29.97% |
| 2013 | 416.58% |
| 2012 | 328.70% |
| 2011 | 23.06% |
| 2010 | -30.48% |
| 2009 | 14.05% |
| 2008 | -90.54% |
| 2007 | 30.89% |
| 2006 | -8.44% |
| 2005 | 48.01% |
| 2004 | 0.00% |
Hasonló cégek vagy versenytársak részvényárai
| Vállalat | Részvényár | Változás 1év% | Ország |
|---|---|---|---|
| $531.67 | 24.68% |
US
|
|
| $237.10 | 783.04% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $895.07 | 9.94% |
NL
|
|
| $288.17 | 1.24% |
BE
|
